摘要
目的探究恩替卡韦联合护肝药物治疗慢性乙肝肝硬化的临床效果及对肝功能的影响。方法以2020年1月-2021年1月80例慢性乙肝肝硬化患者为研究对象,应用随机数字表法分组,对照组采用护肝药物治疗,试验组采用恩替卡韦与护肝药物联合治疗,分析两组治疗结果的差异性。结果试验组总有效率为92.50%,高于对照组总有效率72.50%,χ^(2)=5.541,P=0.019;两组治疗后ALP、AST、ALT等肝功能指标水平均低于治疗前,差异有统计学意义(P<0.05);试验组治疗后ALP水平(70.26±4.22)U/L、AST水平(35.12±6.39)U/L、ALT水平(33.70±6.54)U/L低于对照组ALP水平(115.61±11.06)U/L、AST水平(43.79±8.22)U/L、ALT水平(43.56±5.82)U/L,t=24.229、5.267、7.123,差异有统计学意义(P<0.05)。结论慢性乙肝肝硬化患者接受恩替卡韦与护肝药物联合治疗,可提高治疗的效果,更好改善肝功能指标水平。
Objective To explore the clinical effect of entecavir combined with hepatoprotective drugs in the treatment of chronic hepatitis B cirrhosis and its influence on liver function.Methods A total of 80 patients with chronic hepatitis B cirrhosis from January 2020 to January 2021 were randomly divided into two groups by random number method:the control group was treated with liver-protecting drugs,and the experimental group was treated with entecavir and liver-protecting drugs.The difference in the treatment results between the two groups was analyzed.Results The total effective rate was 92.50%,higher than 72.50%in the control group,χ^(2)=5.541,P=0.019.After treatment,liver function indexes such as ALP,AST and ALT were all lower in both groups than before treatment,the difference wasstatistically significant(P<0.05).After treatment,ALP(70.26±4.22)U/L,AST(35.12±6.39)U/L,ALT(33.70±6.54)UL in the experimental group,lower than those in the control group,ALP(115.61±11.06)U/L,AST(43.7918.22)U/L,ALT(43.56±5.82)U/L,t=24.229,5.267,7.123,the difference was statistically significant(P<0.05).Conclusion The combined trcatment of entecavir and liver-protecting drugs in patients with chronic hepatitis B cirrhosis can improve the therapeutic effect and the level of liver function indexes.
作者
杨庆余
费勇
YANG Qingyu;FEI Yong(Department of Infection,Gaochun People’s Hospital,Nanjing Jiangsu 211300,China)
出处
《中国卫生标准管理》
2022年第1期86-89,共4页
China Health Standard Management
关键词
恩替卡韦
护肝药物
慢性乙肝肝硬化
肝功能
碱性磷酸酶
天门冬氨酸氨基转移酶
entecavir
hepatoprotective drugs
chronic hepatitis B cirrhosis
liver function
alkaline phosphatase
aspartate aminotransferase
